269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 [臨床試験数:20,薬物数:26(DrugBank:10),標的遺伝子数:12,標的パスウェイ数:90

Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03311464October 27, 201712/10/2017A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in JapanA Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in JapanPyoderma GangrenosumDrug: adalimumabAbbVieNULLCompleted18 YearsN/AAll22Phase 3Japan
2NCT00730717May 20094/8/2008Safety and Efficacy Study of Humira in Treatment of Pyoderma GangrenosumMulti Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumDrug: HumiraWright State UniversityStanford University;Wake Forest School of MedicineWithdrawn18 YearsN/ABoth20Phase 2United States
3NCT00690846July 20072/6/2008Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumA Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)Pyoderma GangrenosumDrug: adalimumabWake Forest University Health SciencesNULLWithdrawn18 YearsN/AAll0Phase 2United States